About Okklo Life Sciences
Okklo Life Sciences is a privately held biopharmaceutical company developing novel therapeutic solutions using cyclodextrin-based technologies, with a focus on neglected and orphan diseases.
The company was founded in December 2011 by a team of life-sciences experts previously involved in the development and approval of sugammadex (Bridion™), the first modified cyclodextrin (CD) marketed as a drug product.
What we offer
- Unique expertise in development of cyclodextrin-based therapeutics
- Track-record of successful submissions and approvals in EU, US and Japan
- SME partner in collaborative (pre-competitive) projects
- Partnering and licensing opportunities